DELCATH SYSTEMS, INC. 8-K

What Happened
Delcath Systems, Inc. (DCTH) filed an 8-K on March 3, 2026 (Item 8.01) announcing that the results of its CHOPIN clinical trial were published in The Lancet Oncology. The company issued a press release about the publication, which was furnished as Exhibit 99.1 to the filing.

Key Details

• Date of filing and press release: March 3, 2026.
• Study: CHOPIN clinical trial (publication announced in The Lancet Oncology).
• Filing item: Item 8.01 (Other Events) — press release furnished as Exhibit 99.1.
• The 8-K does not include financial results, changes in management, or other operational disclosures.

Why It Matters
A peer‑reviewed publication in The Lancet Oncology is a notable scientific milestone that can increase visibility and credibility of Delcath’s clinical data with physicians, regulators, and investors. For retail investors, this event signals progress on the company’s clinical development program, though the 8‑K itself does not provide new financial or regulatory outcomes. Investors should review the press release and the full Lancet Oncology article (as available) for the detailed clinical results and implications.